Hepatocyte growth factor (HGF), whose tissue and serum expression levels are related to a poor prognosis of CRC patients, is secreted mostly from mesenchymal tissues and is currently the only known ligand for the receptor tyrosine kinase known as mesenchymal–epithelial transition factor (c-MET or MET) that is active in tumor proliferation, survival, metastasis, and acquired drug resistance [69]. This evidence concerns the gene MET and neoplasm.